Across TCGA pan-cancer cohorts, ANKRD35 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ANKRD35 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ANKRD35 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ANKRD35 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where ANKRD35 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.772	0.332	.004	45	view →
LUAD	OS	Tertile	II,III,IV	0.832	1.000	.016	34	view →
HNSC	OS	Median	All	1.000	0.449	.023	6	view →
LSCC	OS	Median	III,IV	0.908	0.530	.014	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ANKRD35 tumor-vs-normal RNA expression · all ANKRD35 data types